Subsequently, tumors from the BIG 02-98 trial revealed that TILs are associated with clinical benefit from adjuvant chemotherapy in patients with TNBC and HER2-positive (HER2+) breast cancer (19). Here, ERBB2 is linked to breast carcinoma.